Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR

Acrivon Therapeutics, Inc.

2024-Q2 EPS reported -$1.20

Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.
Cash, equivalents and marketable securities $220.4M expected to fund into H2 2026.
ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive gynecological cancer patients.
ACR-2316 WEE1/PKMYT1 inhibitor Phase 1 on track to start 4Q 2024.
Raised $130M in oversubscribed private placement financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.